UNSPSC 50501522: Paricalcitol

This classification denotes a vitamin d analog, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 6702D36OG5. European Medicines Agency schedules Paricalcitol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09627MIG. Paricalcitol generally arises in the molecular formula C27H44O3.

The term PARICALCITOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 12 no. 2 1999, list 40.) PARICALCITOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 50501522 Paricalcitol is a Commodity code covering the procurement of paricalcitol, a vitamin D analogue medication used primarily in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. State and local governments acquire paricalcitol through their health departments, Medicaid agencies, correctional health systems, and public hospital networks to supply inpatient and outpatient clinical settings. The code captures both branded and generic formulations, typically in injectable or oral dosage forms, procured as part of broader pharmaceutical inventory management or disease-state specific medication protocols.

The most-recent-state-local-contract-opportunities block provided no entries for this code. State and local procurement activity under UNSPSC 50501522 does not appear in the available recent solicitation records, suggesting either minimal open-market competitive procurement at the state and local level for this specific pharmaceutical or consolidation of paricalcitol purchasing through existing group purchasing organization (GPO) contracts, state Medicaid formulary arrangements, or federal supply schedules that bypass individual RFP cycles.